Charles River Laboratories International Inc
Change company Symbol lookup
Select an option...
CRL Charles River Laboratories International Inc
PACD Pacific Drilling SA
AUHEF Anhui Expressway Co Ltd
BAC Bank of America Corp
CMSQF Computershare Ltd
UNH UnitedHealth Group Inc
RYAAY Ryanair Holdings PLC
FNGO MicroSectors? FANG+? Index 2X Leveraged ETN
VIVC Vivic Corp
LAD Lithia Motors Inc
Go

Health Care : Life Sciences Tools & Services | Mid Cap Growth
Company profile

Charles River Laboratories International, Inc. is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development. The Company operates in three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). The RMS segment includes Research Models and Research Model Services. The DSA segment includes Discovery Services and Safety Assessment. The Manufacturing segment includes Microbial Solutions, Avian, Biologics and Contract Manufacturing. The Company also provides a suite of products and services to support the Company's clients' manufacturing activities.

Closing Price
$227.70
Day's Change
-1.24 (-0.54%)
Bid
--
Ask
--
B/A Size
--
Day's High
229.74
Day's Low
220.87
Volume
(Heavy Day)
Volume:
488,724

10-day average volume:
378,363
488,724

CRL's position in the Life Sciences Tools & Services industry

Industry PeersCRLIQVPRAHSYNHMEDP

Summary

Company ProfileCharles River Laboratories International, Inc. is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop...
IQVIA Holdings Inc., formerly Quintiles IMS Holdings, Inc., provides integrated information and technology-enabled healthcare services. The Company operates through segments, including Commercial...
Go to IQV summary
PRA Health Sciences, Inc. is a contract research organization. The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The Company offers...
Go to PRAH summary
Syneos Health Inc. is a fully integrated biopharmaceutical solutions providing company. The Company offers both stand-alone and integrated biopharmaceutical product development solutions through its...
Go to SYNH summary
Medpace Holdings, Inc. is a clinical contract research organization. The Company provides clinical research-based drug and medical device development services. The Company partners with...
Go to MEDP summary
52-Week Change

VS. INDUSTRY
75.18%
6.63%
-0.28%
5.84%
48.04%
Market Cap

VS. INDUSTRY
$11.3B
$29.5B
$6.2B
$5.5B
$4.0B
Beta

VS. INDUSTRY
1.2
1.5
1.2
1.8
1.4
Dividend Yield

VS. INDUSTRY
--
--
--
--
--
P/E (TTM, GAAP)

VS. INDUSTRY
37.96x
171.48x
29.83x
29.17x
33.78x
Data as of

Fundamentals

Total Revenue (TTM)

VS. INDUSTRY
$2.8B
$11.0B
$3.1B
$4.5B
$896.1M
Profit Margin

VS. INDUSTRY
10.68%
1.81%
6.86%
4.28%
13.87%
Earnings Growth
(5 year, GAAP)

VS. INDUSTRY
13.43%
-18.85%
--
--
--
Revenue Growth (TTM)

VS. INDUSTRY
11.55%
0.69%
5.52%
-2.60%
8.86%
Data as of
Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Copyright © 2020. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.